This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baud, D. Articles by Nardelli-Haefliger, D. Search for Related Content PubMed PubMed Citation Articles by Baud, D. Articles by Nardelli-Haefliger, D.

 Previous Article  |  Next Article 

Journal of Virology, December 2004, p. 12901-12909, Vol. 78, No. 23
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.23.12901-12909.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Improved Efficiency of a Salmonella-Based Vaccine against Human Papillomavirus Type 16 Virus-Like Particles Achieved by Using a Codon-Optimized Version of L1

David Baud, Françoise Ponci, Martine Bobst, Pierre De Grandi, and Denise Nardelli-Haefliger^*

Department of Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Received 7 May 2004/ Accepted 20 July 2004

Cervical cancer results from cervical infection by human papillomaviruses (HPVs), especially HPV16. An effective vaccine against these HPVs is expected to have a dramatic impact on the incidence of this cancer and its precursor lesions. The leading candidate, a subunit prophylactic HPV virus-like particle (VLP) vaccine, can protect women from HPV infection. An alternative improved vaccine that avoids parenteral injection, that is efficient with a single dose, and that induces mucosal immunity might greatly facilitate vaccine implementation in different settings. In this study, we have constructed a new generation of recombinant Salmonella organisms that assemble HPV16 VLPs and induce high titers of neutralizing antibodies in mice after a single nasal or oral immunization with live bacteria. This was achieved through the expression of a HPV16 L1 capsid gene whose codon usage was optimized to fit with the most frequently used codons in Salmonella. Interestingly, the high immunogenicity of the new recombinant bacteria did not correlate with an increased expression of L1 VLPs but with a greater stability of the L1-expressing plasmid in vitro and in vivo in absence of antibiotic selection. Anti-HPV16 humoral and neutralizing responses were also observed with different Salmonella enterica serovar Typhimurium strains whose attenuating deletions have already been shown to be safe after oral vaccination of humans. Thus, our findings are a promising improvement toward a vaccine strain that could be tested in human volunteers.

---

* Corresponding author. Mailing address: Département de Gynécologie, c/o Institut de Microbiologie, CHUV, Bugnon 48, 1011 Lausanne, Switzerland. Phone: 41 21 314 40 81. Fax: 41 21 314 40 95. E-mail: dnardell{at}hospvd.ch.

---

Journal of Virology, December 2004, p. 12901-12909, Vol. 78, No. 23
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.23.12901-12909.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Echchannaoui, H., Bianchi, M., Baud, D., Bobst, M., Stehle, J.-C., Nardelli-Haefliger, D. (2008). Intravaginal Immunization of Mice with Recombinant Salmonella enterica Serovar Typhimurium Expressing Human Papillomavirus Type 16 Antigens as a Potential Route of Vaccination against Cervical Cancer. Infect. Immun. 76: 1940-1951 [Abstract] [Full Text]  
• Fraillery, D., Baud, D., Pang, S. Y.-Y., Schiller, J., Bobst, M., Zosso, N., Ponci, F., Nardelli-Haefliger, D. (2007). Salmonella enterica Serovar Typhi Ty21a Expressing Human Papillomavirus Type 16 L1 as a Potential Live Vaccine against Cervical Cancer and Typhoid Fever. CVI 14: 1285-1295 [Abstract] [Full Text]  
• Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A. (2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80: 2621-2630 [Abstract] [Full Text]